Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire•23/10/2026•16:15 ET
0
Key Highlights
- ➤45,750 stock options and 2,775 RSUs granted to 16 newly hired employees
- ➤$39.22 exercise price matches Nektar’s October 20 closing stock price
- ➤Inducement Plan expanded by 250,000 shares to 500,000 total capacity
- ➤Options vest over four years and expire after eight years
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.
Get started
Create a free account to read the full story.